| 1 | [SID103755823] | Active | Ki | 0.00017 | Displacement of [3H](S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R expressed in CHO cells after 3 hrs by scintillation counting [AID482635, Type: Literature] | Orexin receptor type 2 [gi:206729885] |   View X | Row No. | 1 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | Ki | 0.00017 [uM] | | BioAssay | Displacement of [3H](S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R expressed in CHO cells after 3 hrs by scintillation counting | | AID | 482635 | | BioAssay type | Literature | | Target | Orexin receptor type 2 [gi:206729885] | | PubMed | 20565075 | | Data Table |  |
|
| 2 | [SID103755823] | Active | Ki | 0.00017 | Displacement of [3H](S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R expressed in CHO cells after 3 hrs by scintillation counting [AID482635, Type: Literature] | Orexin receptor type 2 [gi:206729885] |   View X | Row No. | 2 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | Ki | 0.00017 [uM] | | BioAssay | Displacement of [3H](S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R expressed in CHO cells after 3 hrs by scintillation counting | | AID | 482635 | | BioAssay type | Literature | | Target | Orexin receptor type 2 [gi:206729885] | | PubMed | 20565075 | | Data Table |  |
|
| 3 | [SID103755823] | Active | Ki | 0.0018 | Displacement of [3H](S)-N-(biphenyl-2-yl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX1R expressed in CHO cells after 3 hrs by scintillation counting [AID482633, Type: Literature] | Orexin receptor type 1 [gi:205804177] |   View X | Row No. | 3 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | Ki | 0.0018 [uM] | | BioAssay | Displacement of [3H](S)-N-(biphenyl-2-yl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX1R expressed in CHO cells after 3 hrs by scintillation counting | | AID | 482633 | | BioAssay type | Literature | | Target | Orexin receptor type 1 [gi:205804177] | | PubMed | 20565075 | | Data Table |  |
|
| 4 | [SID103755823] | Active | Ki | 0.0018 | Displacement of [3H]N-cyclobutyl-5-methyl-N-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)ethyl)-2-(2H-1,2,3-triazol-2-yl)benzamide from human OX1R expressed in CHO cells after 20 hrs by scintillation counting [AID482634, Type: Literature] | Orexin receptor type 1 [gi:205804177] |   View X | Row No. | 4 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | Ki | 0.0018 [uM] | | BioAssay | Displacement of [3H]N-cyclobutyl-5-methyl-N-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)ethyl)-2-(2H-1,2,3-triazol-2-yl)benzamide from human OX1R expressed in CHO cells after 20 hrs by scintillation counting | | AID | 482634 | | BioAssay type | Literature | | Target | Orexin receptor type 1 [gi:205804177] | | PubMed | 20565075 | | Data Table |  |
|
| 5 | [SID103755823] | Active | Ki | 0.0018 | Displacement of [3H](S)-N-(biphenyl-2-yl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX1R expressed in CHO cells after 3 hrs by scintillation counting [AID482633, Type: Literature] | Orexin receptor type 1 [gi:205804177] |   View X | Row No. | 5 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | Ki | 0.0018 [uM] | | BioAssay | Displacement of [3H](S)-N-(biphenyl-2-yl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX1R expressed in CHO cells after 3 hrs by scintillation counting | | AID | 482633 | | BioAssay type | Literature | | Target | Orexin receptor type 1 [gi:205804177] | | PubMed | 20565075 | | Data Table |  |
|
| 6 | [SID103755823] | Active | Ki | 0.0018 | Displacement of [3H]N-cyclobutyl-5-methyl-N-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)ethyl)-2-(2H-1,2,3-triazol-2-yl)benzamide from human OX1R expressed in CHO cells after 20 hrs by scintillation counting [AID482634, Type: Literature] | Orexin receptor type 1 [gi:205804177] |   View X | Row No. | 6 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | Ki | 0.0018 [uM] | | BioAssay | Displacement of [3H]N-cyclobutyl-5-methyl-N-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)ethyl)-2-(2H-1,2,3-triazol-2-yl)benzamide from human OX1R expressed in CHO cells after 20 hrs by scintillation counting | | AID | 482634 | | BioAssay type | Literature | | Target | Orexin receptor type 1 [gi:205804177] | | PubMed | 20565075 | | Data Table |  |
|
| 7 | [SID103755823] | Active | IC50 | 0.027 | Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay [AID482636, Type: Literature] | Orexin receptor type 1 [gi:205804177] |   View X | Row No. | 7 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | IC50 | 0.027 [uM] | | BioAssay | Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay | | AID | 482636 | | BioAssay type | Literature | | Target | Orexin receptor type 1 [gi:205804177] | | PubMed | 20565075 | | Data Table |  |
|
| 8 | [SID103755823] | Active | IC50 | 0.027 | Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay [AID482636, Type: Literature] | Orexin receptor type 1 [gi:205804177] |   View X | Row No. | 8 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | IC50 | 0.027 [uM] | | BioAssay | Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay | | AID | 482636 | | BioAssay type | Literature | | Target | Orexin receptor type 1 [gi:205804177] | | PubMed | 20565075 | | Data Table |  |
|
| 9 | [SID103755823] | Active | IC50 | 0.027 | Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay [AID482637, Type: Literature] | Orexin receptor type 2 [gi:206729885] |   View X | Row No. | 9 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | IC50 | 0.027 [uM] | | BioAssay | Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay | | AID | 482637 | | BioAssay type | Literature | | Target | Orexin receptor type 2 [gi:206729885] | | PubMed | 20565075 | | Data Table |  |
|
| 10 | [SID103755823] | Active | IC50 | 0.027 | Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay [AID482637, Type: Literature] | Orexin receptor type 2 [gi:206729885] |   View X | Row No. | 10 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | IC50 | 0.027 [uM] | | BioAssay | Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium mobilization after 5 mins by FLIPR assay | | AID | 482637 | | BioAssay type | Literature | | Target | Orexin receptor type 2 [gi:206729885] | | PubMed | 20565075 | | Data Table |  |
|
| 11 | [SID103755823] | Active | | | Antiinsomnic activity in Sprague-Dawley rat assessed as decrease in active wake duration at 10 mg/kg/day, po 30 mg/kg/day [AID482824, Type: Literature] | |   View X | Row No. | 11 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | BioAssay | Antiinsomnic activity in Sprague-Dawley rat assessed as decrease in active wake duration at 10 mg/kg/day, po 30 mg/kg/day | | AID | 482824 | | BioAssay type | Literature | | Target | | | PubMed | 20565075 | | Data Table |  |
|
| 12 | [SID103755823] | Active | | | Antiinsomnic activity in Sprague-Dawley rat assessed as increase in rapid-eye movement at 10 mg/kg/day, po measured with 3 to 4 hrs post last dose [AID482825, Type: Literature] | |   View X | Row No. | 12 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | BioAssay | Antiinsomnic activity in Sprague-Dawley rat assessed as increase in rapid-eye movement at 10 mg/kg/day, po measured with 3 to 4 hrs post last dose | | AID | 482825 | | BioAssay type | Literature | | Target | | | PubMed | 20565075 | | Data Table |  |
|
| 13 | [SID103755823] | Active | | | Antiinsomnic activity in Sprague-Dawley rat assessed as increase in delta sleep duration at 10 mg/kg/day, po measured with 3 to 4 hrs post last dose [AID482826, Type: Literature] | |   View X | Row No. | 13 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | BioAssay | Antiinsomnic activity in Sprague-Dawley rat assessed as increase in delta sleep duration at 10 mg/kg/day, po measured with 3 to 4 hrs post last dose | | AID | 482826 | | BioAssay type | Literature | | Target | | | PubMed | 20565075 | | Data Table |  |
|
| 14 | [SID103755823] | Active | | | Antiinsomnic activity in Sprague-Dawley rat assessed as decrease in light sleep duration at 10 mg/kg/day, po measured with 3 to 4 hrs post last dose [AID482827, Type: Literature] | |   View X | Row No. | 14 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | BioAssay | Antiinsomnic activity in Sprague-Dawley rat assessed as decrease in light sleep duration at 10 mg/kg/day, po measured with 3 to 4 hrs post last dose | | AID | 482827 | | BioAssay type | Literature | | Target | | | PubMed | 20565075 | | Data Table |  |
|
| 15 | [SID103755823] | Active | | | Drug level in Sprague-Dawley rat plasma at 10 mg/kg/day, po after 1 hr [AID482828, Type: Literature] | |   View X | Row No. | 15 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | BioAssay | Drug level in Sprague-Dawley rat plasma at 10 mg/kg/day, po after 1 hr | | AID | 482828 | | BioAssay type | Literature | | Target | | | PubMed | 20565075 | | Data Table |  |
|
| 16 | [SID103755823] | Active | | | Drug level in Sprague-Dawley rat CSF at 10 mg/kg/day, po after 1 hr [AID482829, Type: Literature] | |   View X | Row No. | 16 | | Structure |
| | Substance | | | SID | 103755823 | | CID | 24808514 | | Outcome | Active | | BioAssay | Drug level in Sprague-Dawley rat CSF at 10 mg/kg/day, po after 1 hr | | AID | 482829 | | BioAssay type | Literature | | Target | | | PubMed | 20565075 | | Data Table |  |
|